SG72191G - Solid galenical forms for oral application containing 9-deoxo 11-deoxy-9,11-(imino(2(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin,and process for their preparation - Google Patents

Solid galenical forms for oral application containing 9-deoxo 11-deoxy-9,11-(imino(2(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin,and process for their preparation

Info

Publication number
SG72191G
SG72191G SG721/91A SG72191A SG72191G SG 72191 G SG72191 G SG 72191G SG 721/91 A SG721/91 A SG 721/91A SG 72191 A SG72191 A SG 72191A SG 72191 G SG72191 G SG 72191G
Authority
SG
Singapore
Prior art keywords
deoxo
erythromycin
methoxyethoxy
deoxy
imino
Prior art date
Application number
SG721/91A
Other languages
English (en)
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of SG72191G publication Critical patent/SG72191G/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG721/91A 1985-07-10 1991-08-26 Solid galenical forms for oral application containing 9-deoxo 11-deoxy-9,11-(imino(2(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin,and process for their preparation SG72191G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853524572 DE3524572A1 (de) 1985-07-10 1985-07-10 Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
SG72191G true SG72191G (en) 1991-11-22

Family

ID=6275375

Family Applications (1)

Application Number Title Priority Date Filing Date
SG721/91A SG72191G (en) 1985-07-10 1991-08-26 Solid galenical forms for oral application containing 9-deoxo 11-deoxy-9,11-(imino(2(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin,and process for their preparation

Country Status (25)

Country Link
US (1) US4755385A (fr)
EP (1) EP0208971B1 (fr)
JP (1) JPH0688905B2 (fr)
KR (1) KR930010586B1 (fr)
AT (1) ATE63819T1 (fr)
AU (1) AU586262B2 (fr)
CA (1) CA1271138A (fr)
DD (1) DD248057A5 (fr)
DE (2) DE3524572A1 (fr)
DK (1) DK165670C (fr)
ES (1) ES2000269A6 (fr)
FI (1) FI85649C (fr)
GR (1) GR861762B (fr)
HK (1) HK79791A (fr)
HU (1) HU195730B (fr)
IE (1) IE58951B1 (fr)
IL (1) IL79375A (fr)
MX (1) MX9202785A (fr)
NL (1) NL970004I2 (fr)
NO (1) NO175351C (fr)
NZ (1) NZ216794A (fr)
PH (1) PH26147A (fr)
PT (1) PT82949B (fr)
SG (1) SG72191G (fr)
ZA (1) ZA865105B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4945080A (en) * 1987-05-26 1990-07-31 Eli Lilly And Company Dirithromycin metabolite
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
ES2199981T3 (es) * 1994-02-16 2004-03-01 Abbott Laboratories Modo de preparacion de formulaciones farmaceuticas de particulas finas.
ES2163504T5 (es) * 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
US6045843A (en) * 1995-12-22 2000-04-04 Tamer International, Inc. Acid-reduced, whole bean coffee process
US5853787A (en) * 1995-12-22 1998-12-29 Tamer International Method for reducing coffee acidity
US6495180B1 (en) 1995-12-22 2002-12-17 Tamer International, Ltd. Acid reduced whole bean coffee and process
US6066342A (en) * 1995-12-22 2000-05-23 Tamer International, Ltd. Antacid composition
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6096328A (en) 1997-06-06 2000-08-01 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6582708B1 (en) 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
US20020018754A1 (en) * 1999-03-15 2002-02-14 Paul Albert Sagel Shapes for tooth whitening strips
PT1187601E (pt) 1999-06-07 2005-11-30 Altana Pharma Ag Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
AU768471B2 (en) 1999-07-02 2003-12-11 Procter & Gamble Company, The Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
DE60122718T2 (de) * 2000-06-28 2007-08-23 The Procter & Gamble Company, Cincinnati Strukturen und zusammensetzungen zur erhöhung der stabilität von aktiven peroxiden
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US6949240B2 (en) * 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
WO2005009364A2 (fr) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation associees
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
EP1648407A4 (fr) 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc Produit antibiotique, utilisation et formulation correspondantes
EP1653925A1 (fr) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Pastille robuste
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1658034A4 (fr) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Produit antibiotique, son utilisation et sa formulation
CA2538064C (fr) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotique, son utilisation et sa formulation
WO2006014427A1 (fr) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Comprimé pour distribution par impulsion
RU2403033C2 (ru) 2005-03-22 2010-11-10 Лозан Фарма Гмбх Солюбилизированный ибупрофен
JP2009502908A (ja) * 2005-07-29 2009-01-29 スティッチング グロニンゲン セントル フォー ドラッグ リサーチ ｐＨ制御パルス送達システム、その調製法及び使用法
US20080255048A1 (en) * 2005-11-17 2008-10-16 Moise Azria Pharmaceutical Composition
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
TW200800233A (en) * 2006-04-28 2008-01-01 Shionogi & Amp Co Ltd A coated preparation of macrolide antibiotics
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
BR112015008666B1 (pt) 2012-10-17 2020-04-07 Procter & Gamble produto extensível para tratamento dental e método de aplicação de um ativo para tratamento bucal
GB2533593A (en) * 2014-12-22 2016-06-29 Parkside Flexibles (Europe) Ltd Package

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US3891755A (en) * 1973-07-11 1975-06-24 Abbott Lab Dosage formulation for erythromycin cetyl sulfate
AT342770B (de) * 1975-04-07 1978-04-25 Thomae Gmbh Dr K Verfahren zur herstellung neuer erythromycinderivate
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法

Also Published As

Publication number Publication date
AU5987686A (en) 1987-01-15
DK324786A (da) 1987-01-11
US4755385A (en) 1988-07-05
DE3679463D1 (de) 1991-07-04
ES2000269A6 (es) 1988-02-01
EP0208971A2 (fr) 1987-01-21
PT82949A (de) 1986-08-01
FI85649C (fi) 1992-05-25
NO862772D0 (no) 1986-07-09
IE861842L (en) 1987-01-10
PH26147A (en) 1992-03-18
DD248057A5 (de) 1987-07-29
FI85649B (fi) 1992-02-14
AU586262B2 (en) 1989-07-06
NO862772L (no) 1987-01-12
IL79375A (en) 1990-01-18
KR870000920A (ko) 1987-03-10
HUT42945A (en) 1987-09-28
NZ216794A (en) 1988-11-29
GR861762B (en) 1986-11-10
NO175351C (no) 1994-10-05
NO175351B (no) 1994-06-27
FI862898A (fi) 1987-01-11
HU195730B (en) 1988-07-28
NL970004I2 (nl) 1997-06-02
DK324786D0 (da) 1986-07-08
IL79375A0 (en) 1986-10-31
KR930010586B1 (ko) 1993-10-30
EP0208971A3 (en) 1988-01-27
MX9202785A (es) 1992-06-30
HK79791A (en) 1991-10-18
JPH0688905B2 (ja) 1994-11-09
ATE63819T1 (de) 1991-06-15
IE58951B1 (en) 1993-12-01
JPS6212717A (ja) 1987-01-21
DK165670C (da) 1993-06-07
PT82949B (pt) 1989-01-30
NL970004I1 (nl) 1997-04-01
DK165670B (da) 1993-01-04
CA1271138A (fr) 1990-07-03
DE3524572A1 (de) 1987-01-15
EP0208971B1 (fr) 1991-05-29
FI862898A0 (fi) 1986-07-10
ZA865105B (en) 1988-03-30

Similar Documents

Publication Publication Date Title
SG72191G (en) Solid galenical forms for oral application containing 9-deoxo 11-deoxy-9,11-(imino(2(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin,and process for their preparation
HUT58511A (en) Process for producing pharmaceutical compositions comprising toremifen and its metabolites, suitable for ceasing the simultaneous resistance of cancer cells to several cytotoxic active ingredients
EP0395329A3 (fr) composition sous forme de mousse contenant l'acide amino-5 salicylique pour administration intra-rectale
IL87290A0 (en) Epipodophyllotoxin glucoside 4'-phosphate derivatives,their preparation and pharmaceutical compositions containing them
HUT47130A (en) Process for producing 9alpha-hydroxysteroids, as well as 9(11)-dehydro derivatives and pharmaceutical compositions comprising these active ingredients
ZA888734B (en) Stabilized medicinal substances,a process for the preparation thereof,and stable medicinal formulations
IE852593L (en) Compositions containing anthracycline glycosides
Friedman The effect of 5-azacytidine on E. coli DNA methylase
CS8804389A2 (en) Method of pharmaceutical preparation formulation with laminar structure for transdermal administration of active substance with null kinetic order
HU893631D0 (en) Process for producing 1,1-dioxo-cephem-4-carbothiolic acid derivatives and pharmaceutical prepartives containing them as active substance
HUT53113A (en) Process for production of hindering tumour platina (iv) diamin komplex and medical compositions containing them as active substance
PT80131A (en) Process for the preparation of pharmaceutical compositions in liquid dosage form suitable for oral administration of 4'-demethylepipodophyllotoxin-9-<4,6-o(r)-ethylidene-beta-d-glucopyranoside>(etoposide)
ES500185A0 (es) Un metodo para la preparacion de una formulacion farmaceutica de un antibiotico glicosidico o similar.
IL83495A0 (en) Oxirane pseudooligosaccharides,a process for their preparation,and pharmaceutical preparations containing them
AU5024185A (en) 1,3,4-Thiadiazole derivatives, processes for their preparation, and pharmaceutical preparations containing these compounds
JPS6442430A (en) Side effect remover for chemotherapeutic agent
FR2646158B1 (fr) Nouveau procede de preparation d'imidazo (2,1-b) benzothiazoles et leurs sels, les nouveaux produits obtenus, l'application a titre de medicaments de ces nouveaux produits et les compositions pharmaceutiques les renfermant
HU901875D0 (en) Process for production of galenical preparations providing optimal biological accessibility of 2-hydroxi-5-methyl-laurophenon-oxim as active substance
Lucas et al. Sustained Action Tetracycline Preparation–Tetrabid-Organon Blood Level Study
IL84150A0 (en) Sugar derivatives of biologically active peptides,their production and pharmaceutical compositions containing them
JPS6438024A (en) Biostimulant digester and manufacture
GB2213062A (en) Pharmaceutical preparation having oestrogen action
ES8707665A3 (es) Procedimiento de produccion de preparados farmaceuticos conteniendo al menos una materia activa farmaceutica,especialmente una materia activa insoluble o dificil o lentamente soluble.